8-K: KORU Medical Systems Q1 2026 Results Show Strong Revenue Growth

KORU Medical Systems reported a 22% increase in first-quarter net revenues to $11.8 million, driven by core business growth and international expansion, while also reiterating full-year 2026 financial guidance.

Summary

• KORU Medical Systems announced its financial results for the first fiscal quarter ended March 31, 2026.
• Net revenues reached $11.8 million, a 22.1% increase compared to the prior year period.
• Gross profit grew by 19.6% to $7.2 million, with a gross margin of 61.5%.
• The net loss improved by 31% to $0.8 million, or ($0.02) per diluted share.
• The company maintained an ending cash balance of $8.8 million, with a cash usage of $0.1 million in the quarter.
• KORU Medical reiterated its full-year 2026 guidance for net revenues between $47.5 - $50.0 million and a gross margin of 61-63%.
• The company also expects positive adjusted EBITDA and positive cash flow for the full year 2026.
• A 510(k) application was submitted for the Freedom Infusion System with deferoxamine, and two non-Ig pharma collaborations advanced to Phase III clinical trials.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth and improved net loss, alongside reiterated positive full-year guidance, indicating solid operational performance and strategic execution.

Positives

• First quarter 2026 net revenues of $11.8 million grew 22% over the prior year period.
• First quarter 2026 gross profit grew 20% over the prior year period to $7.2 million, with gross margin of 61.5%.
• First quarter 2026 net loss improved 31% to ($0.8) million, a decrease from ($1.2) million in the prior year.
• Domestic core revenues increased by 11.7% due to higher consumable volumes and market share gains.
• International core revenues increased by 35.2% driven by distributor purchases for pre-filled syringe conversions.
• Pharma services and clinical trials net revenues increased by 166.0% due to higher clinical trial product revenues.
• The company reiterated its full-year 2026 revenue guidance of $47.5 - $50.0 million, representing 15% - 22% growth.
• Full-year 2026 gross margin guidance remains between 61% - 63%.

Negatives

• Gross margin decreased slightly to 61.5% from 62.8% in the prior year, primarily due to higher production costs and tariff-related charges.
• Total operating expenses increased by 11.0% to $8.1 million, driven by higher selling, general, and administrative expenses, including legal fees and compensation expenses.
• The company reported a net loss of $0.8 million for the quarter.
• Adjusted EBITDA for the quarter was ($0.01) million, a slight improvement from ($0.2) million in the prior year but still negative.

Risks

• Uncertainties associated with inflation, tariffs, war and other geopolitical conflicts.
• Availability and costs of raw materials and labor, and the ability to recover such costs.
• Compliance with Food and Drug Administration and foreign authority regulations, and the outcome of regulatory audits.
• Introduction and adoption of competitive products.
• Acceptance of and demand for new and existing products.
• Reimbursement related risks.
• Government regulation of the home health care industry.
• Dependence on key personnel.

Future Outlook

KORU Medical reiterates its full-year 2026 guidance, expecting net revenues between $47.5 million and $50.0 million, representing 15% to 22% growth. The company also anticipates a gross margin between 61% and 63%, positive adjusted EBITDA, and positive cash flow for the full year.

Management Comments

• "We are proud to deliver a record start to 2026, with $11.8 million in revenue, representing 22% growth," said Linda Tharby, CEO of KORU Medical.
• "Our Core business continues to outperform the underlying SCIg market, driven increased share gains in current and new accounts."
• "Internationally, momentum remains robust as we expand into prefilled syringe markets with our patient-preferred Freedom Infusion System."
• "With a growing recurring patient base and scalable commercial model, Koru is well positioned for further success."
• Adam Kalbermatten, President and Chief Commercial Officer, stated, "Equally exciting to our strength in core markets is the momentum we are building in new drug categories with our support of late-stage molecules through their regulatory pathways, including compelling oncology opportunities ahead."
• "A strong team, a clear strategic roadmap, and an expanding platform to access new therapies and new geographies, makes me confident in our long-term strategy and the strong foundation we have built to execute."

Industry Context

StockSavvy.ai notes that KORU Medical's reported revenue growth of 22% in Q1 2026 aligns with the broader trend of increasing demand for innovative infusion solutions in the medical technology sector, particularly for subcutaneous drug delivery.

Comparison to Industry Standards

• The reported gross margin of 61.5% is strong for a medical device company, often exceeding industry averages which can range from 40-60% depending on product complexity and manufacturing scale.
• The net loss, while improved, is not uncommon for growth-stage medical technology companies investing heavily in R&D and market expansion, a pattern seen in companies like Insulet Corporation (PODD) or Tandem Diabetes Care (TNDM) during their growth phases.
• The company's focus on subcutaneous infusion solutions places it in a growing segment of the pharmaceutical delivery market, competing with traditional intravenous methods and other advanced delivery systems.

Legal Proceedings

• The company incurred legal fees related to a patent infringement claim in Q1 2025, which is noted as a litigation expense.

Stakeholder Impact

• Shareholders: Positive impact from revenue growth and reiterated positive full-year outlook, though net loss persists.
• Employees: Potential for increased compensation expenses noted, which could be positive for employees but adds to operating costs.
• Customers: Continued supply of infusion solutions and potential for new applications (deferoxamine) and drug categories.
• Suppliers: Increased demand for consumables and pumps due to revenue growth.

Next Steps

• Continue to expand into prefilled syringe markets internationally.
• Support late-stage molecules through regulatory pathways, including oncology opportunities.
• Monitor progress of the 510(k) application for the Freedom Infusion System with deferoxamine.
• Advance existing non-Ig pharma collaborations through Phase III clinical trials.

Key Dates

Recommendation

The company demonstrates strong revenue growth and operational improvements, meeting expectations and reiterating positive full-year guidance. However, the continued net loss and negative adjusted EBITDA, coupled with ongoing risks in the medical device industry, warrant a 'hold' recommendation until sustained profitability is achieved and the company demonstrates consistent positive cash flow generation.

Keywords

KORU Medical Systems, 8-K Filing, Q1 2026 Results, Medical Technology, Subcutaneous Infusion, Financial Guidance, Revenue Growth, Net Loss